Biogen Reports Long-Term Tysabri Data Showing Sustained Efficacy in Relapsing MS

Biogen today presented long-term real-world data from multiple observational studies showing that Tysabri (natalizumab) maintains sustained reduction in annualized relapse rates and disability progression in patients with relapsing multiple sclerosis over up to 10 years of treatment. The data showed that patients who remained on Tysabri had better long-term outcomes compared to those who switched to other therapies.